KBI Biopharma, Inc., a JSR Life Sciences company, launched SUREmAb, an offering built on KBI’s SUREtechnology Platform designed for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.
SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as nine weeks and the ability for customers to move from DNA to GMP drug substance in as few as 11 months, according to the company. In addition, SUREmAb is engineered to achieve titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and maximize ROI.
According to the company, the operational consolidation of KBI Biopharma and Selexis, played an important role in the operations that power the SUREmAb technology, enabling KBI to streamline processes and offer greater efficiencies in monoclonal antibody development and manufacturing.
